权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mesenteric Fat Cryolipolysis to Reverse Insulin Resistance

肠系膜脂肪冷冻溶脂逆转胰岛素抵抗

基本信息

批准号：
10603168
负责人：
Rafi Mazor
金额：
$ 30万
依托单位：
B2M MEDICAL, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-19 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10603168
关键词：
Abdomen Acute Adipocytes Adopted Adult Anatomy Animal Model Blood Vessels Cardiovascular system Cell Death Cells Central obesity Chronic Clinical Clinical Research Clinical Trials Computer Analysis Data Deposition Development Device Designs Device Safety Devices Diabetes Mellitus Drainage procedure Epidemic Evaluation Excision Family suidae Fatty acid glycerol esters Feasibility Studies Female Financial Hardship Finite Element Analysis Freezing Functional disorder Gender Glucose Greater omentum Health Health Care Costs Hepatic High Fat Diet High temperature of physical object Human Impairment Incidence Individual Inflammation Mediators Inflammatory Insulin Resistance Intestines Laparotomy Life Style Lipids Liquid substance Literature Liver Measures Mesentery Metabolic Metabolic syndrome Methods Modality Modeling Morbidity - disease rate Needles Nerve Non-Insulin-Dependent Diabetes Mellitus Nonesterified Fatty Acids Obesity Omentum Operative Surgical Procedures Patients Phase Prediabetes syndrome Prevalence Procedures Property Protocols documentation Risk Role Safety Shapes Skin Small Business Innovation Research Grant Structure Techniques Technology Temperature Testing Thick Tissues Translating Translations Unresectable Validation Visceral fat Water abdominal fat adipokines base cell type cold temperature comorbidity cytokine diabetic patient diabetogenic diet-induced obesity dietary efficacy study feasibility testing first-in-human in vivo insulin sensitivity male minimally invasive mortality neurovascular nonhuman primate novel novel strategies porcine model prototype recruit safety and feasibility safety study safety testing side effect subcutaneous tool treatment duration

项目摘要

Abstract. The prevalence of insulin resistance, type II diabetes, obesity and co-morbidities of the metabolic syndrome is rising. More than 120M US adults are living with diabetes or are pre-diabetics. This carries a huge financial burden, which was estimated at ~$404B in 2019. Visceral fat (but not subcutaneous) and specifically the mesenteric fat, was shown to have a major role in the pathophysiology of insulin resistance and diabetes. Fat cells are more sensitive to low temperatures compared to any other cell type. Fat solidifies at a higher temperature than the freezing temperature of water, forming needle like structures that promote cell death. Induction of fat cell death by low temperatures (cryolipolysis) is already detected at a temperature of +100C. This relatively high temperature is making cryolipolysis an attractive approach to induce mesenteric fat mass loss as a new treatment modality to reduce Insulin resistance and diabetes in patients with visceral obesity. Our objective is to test the feasibility and safety of a novel approach and device to reduce the mass of the mesenteric fat using cold temperatures, as a new treatment option to reverse insulin resistance and the incidence of diabetes. Hypothesis: excessive mesenteric fat is a major contributor to the progression of insulin resistance, diabetes, and the metabolic syndrome. Cold temperatures delivered into the mesenteric fat will promote fat cells loss without injuring surrounding tissues and without any significant side effects. The decrease in mesenteric fat will have beneficial effects on insulin resistance, diabetes progression, and the metabolic syndrome. To test our hypothesis, we propose the following Specific Aims: 1A. To utilize computational heat transfer methods based on Finite Element Analysis (FEA) to model fat thermal cycle for different device temperatures, shapes, materials, and treatment duration. 1B. To validate acute safety and thermal cycle to be used in in-vivo chronic safety and feasibility studies (Aim 2). 2. In the Ossabaw pig model of insulin resistance, to evaluate the safety and feasibility of mesenteric fat cryolipolysis on insulin resistance progression. Milestones: Successfully modeling the thermal cycle in visceral fat will be considered as a first milestone. Building a cryolipolysis prototype device and in vivo validation of tissue temperatures calculated in 1A will be the second milestone. Seven days post-procedure survival without complications will be considered as the third milestone. Successfully and safely reducing the mesenteric fat mass and reversing the progression of insulin resistance (Aim 2) will be the fourth milestone. The successful completion of these studies will show that cryolipolysis of mesenteric fat is a safe and effective way to treat insulin resistance. The device developed, and the results obtained, will pave the way for optimal device design and safety and efficacy studies utilizing envisioned protocols to be eventually translated in human trials.

摘要。胰岛素抵抗、II型糖尿病、肥胖的患病率及代谢的合并症